All News

The FDA is requesting an update to the existing black box to include information regarding the risk of suicidal thinking and behavior in young adults ages 18 to 24 years old during the first two months of treatment.

AzaSite (azithromycin ophthalmic solution) 1% has been approved by the FDA.

Janssen has received word from the FDA giving it the green light to market Invega for long-term maintenance treatment of schizophrenia.

Patients with von Willebrand disease (vWD) undergoing surgery may now benefit from the use of Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) to prevent excessive bleeding during and after surgery.

Newly approved Veramyst, a nasal spray containing fluticasone furoate, will not only improve nasal symptoms associated with allergies but also relieve allergic eye symptoms, according to manufacturer GlaxoSmithKline.

Death rates and heart failure in hospitalized heart attack patients have fallen significantly, due in part to the growing use of cholesterol-lowering drugs, powerful blood thinners, and angioplasty.

Data from a new report reveals that competition from authorized generics during the 180-day exclusivity period leads to lower prices and does not reduce or slow the introduction of new generic pharmaceuticals.

The Patient Safety Solutions address the issues of: look-alike, sound-alike medication names; correct patient identification; handover communications; correct procedure at the correct body site; control of concentrated electrolyte solutions; medication accuracy; catheter and tubing misconnections; needle reuse and injection device safety; and hand hygiene.

Long-acting Lantus (insulin glargine, Sanofi-Aventis) will soon be available in a device that will allow diabetes patients to administer up to 80 units in one injection.

Manufacturers Amgen and Wyeth have received approval from the FDA for a 25 mg/0.5 ml single-use prefilled syringe of etanercept (Enbrel).

The FDA has approved the use of estrogen for the treatment of moderate to severe vaginal dryness and pain with intercourse and for symptoms of vulvar and vaginal atrophy associated with menopause.

Latebreakers: First bird flu vaccine approved

Latebreakers: Warnings issued for Avastin

Latebreakers: New therapy for Paget?s disease

Latebreakers: CDC updates gonorrhea treatment guide

Impetigo is a bacterial skin condition common in children and characterized by blisters that may itch. Now there is a new antibacterial ointment approved to treat this condition. Retapamulin (Altabax 1%, GlaxoSmithKline) is the first of a new class of antibacterials known as pleuromutilins. According to the manufacturer, no other antibacterials use the same specific mode of action.

Latebreakers: CCRx tops for customer satisfaction

Latebreakers: CVS completes label improvements

Latebreakers: Walgreens names new chairman, president

Latebreakers: Nonprofit focuses on helping pharmacies

Latebreakers: Many N.Y. pharmacies fail to offer foreign language labels

Latebreakers: Pfizer to pay nearly $20 million in PBM kickback scheme

Latebreakers Study: High workload, technology, alert systems increase med errors

PBMs should pass savings from e-prescribing to R.Ph.s; family pharmacies; pharmacy and the military; price controls; cleanliness in the pharmacy

NACDS members meet their new association leader, Steven Anderson

From coughs and colds to analgesics, pharmacists give their top two OTC brand recommendations in this exclusive Drug Topics survey.

CMS issues final rule for competitive acquisition program for DMEPOS suppliers

Comparative effectiveness research needed to find the best in drugs, devices, biologicals, and procedures to improve healthcare, contain costs

Drug Topics' exclusive OTC Recommendation Survey 2007 finds that R.Ph.s are providing more OTC recommendations and counseling than ever.